ASSESMENT OF PROGNOSTIC VALUE OF METASTATIC FREE INTERVAL AS OVERALL SURVIVAL SURROGATE IN METASTATIC BREAST CANCER FEMALE PATIENTS
Gowily, A., Elbadry, I., Elsaka, R., Gamal Eldin, N., Abou Madawy, F. (2022). ASSESMENT OF PROGNOSTIC VALUE OF METASTATIC FREE INTERVAL AS OVERALL SURVIVAL SURROGATE IN METASTATIC BREAST CANCER FEMALE PATIENTS. EKB Journal Management System, 4(1), 30-31. doi: 10.21608/alexpo.2022.120212.1362
Ahmed Gowily; Inas Mohamed Elbadry; Rasha Omer Elsaka; Nahla Ahmed Gamal Eldin; Fagr Mohamed Abead Abou Madawy. "ASSESMENT OF PROGNOSTIC VALUE OF METASTATIC FREE INTERVAL AS OVERALL SURVIVAL SURROGATE IN METASTATIC BREAST CANCER FEMALE PATIENTS". EKB Journal Management System, 4, 1, 2022, 30-31. doi: 10.21608/alexpo.2022.120212.1362
Gowily, A., Elbadry, I., Elsaka, R., Gamal Eldin, N., Abou Madawy, F. (2022). 'ASSESMENT OF PROGNOSTIC VALUE OF METASTATIC FREE INTERVAL AS OVERALL SURVIVAL SURROGATE IN METASTATIC BREAST CANCER FEMALE PATIENTS', EKB Journal Management System, 4(1), pp. 30-31. doi: 10.21608/alexpo.2022.120212.1362
Gowily, A., Elbadry, I., Elsaka, R., Gamal Eldin, N., Abou Madawy, F. ASSESMENT OF PROGNOSTIC VALUE OF METASTATIC FREE INTERVAL AS OVERALL SURVIVAL SURROGATE IN METASTATIC BREAST CANCER FEMALE PATIENTS. EKB Journal Management System, 2022; 4(1): 30-31. doi: 10.21608/alexpo.2022.120212.1362

ASSESMENT OF PROGNOSTIC VALUE OF METASTATIC FREE INTERVAL AS OVERALL SURVIVAL SURROGATE IN METASTATIC BREAST CANCER FEMALE PATIENTS

ALEXMED ePosters
Article 1, Volume 4, Issue 1, March 2022, Page 30-31  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2022.120212.1362
View on SCiNiTO View on SCiNiTO
Authors
Ahmed Gowily1; Inas Mohamed Elbadry2; Rasha Omer Elsaka3; Nahla Ahmed Gamal Eldin4; Fagr Mohamed Abead Abou Madawy email 2
1Alexandria Clinical Oncology Department, Faculty of Medicine, Alexandria University, Alexandria Egypt.
2Department of Cancer Management and Research Medical Research Institute, Alexandria University
3Department of Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University
4Department of Community Medicine, Faculty of Medicine, Alexandria University
Abstract
Various surrogate endpoints for overall survival (OS) have been recently used by FDA for drug approval in miscellaneous cancer types. This aims to facilitate the establishment of clinical trials, propose beneficial treatment options after shorter duration of assessment and provides new clinical prognostic tools. Metastasis-Free Survival (MFS) has been proven to be a Strong Surrogate for Overall Survival in Localized Prostate Cancer. However, this surrogacy has not been studied in breast cancer or any other solid tumor.
AIM OF THE WORK:
To determine the prognostic value of metastasis free interval (MFI) to be a surrogate for overall survival after metastasis in female patients with metastatic breast cancer and To compare MFIamong the Breast cancer subtypes in metastatic breast cancer female patients.
Patients and Methods:
Patients
This retrospective study included 332 breast cancer female patients whose data was retrieved from the archives of medical research institute from December 2009 to December 2019. All included patients had an initial diagnosis of stage 1–3 breast cancer and all have developed subsequent distant metastasis.
Keywords
MFI; OS; breast
Supplementary Files
Statistics
Article View: 77